Management of Vasculitis Secondary to Medications

Immediate Actions and Assessment

The American Heart Association recommends stopping dapagliflozin (SGLT2 inhibitor) immediately in patients with drug-induced vasculitis, as part of the management strategy 1
The American Society of Nephrology suggests determining if the vasculitis is life-threatening or organ-threatening versus limited cutaneous involvement, as this dictates whether immunosuppressive therapy is needed beyond drug withdrawal 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend initiating cyclophosphamide plus corticosteroids if there is renal involvement, pulmonary involvement, or other organ-threatening manifestations 2
The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) suggests considering rituximab plus corticosteroids as an alternative if cyclophosphamide is contraindicated or in patients without the most severe disease 2
The American Society of Nephrology recommends adding plasmapheresis if the patient requires dialysis or has rapidly increasing serum creatinine, or for diffuse pulmonary hemorrhage 2

The American Heart Association recommends switching to a calcium channel blocker (amlodipine 2.5-10 mg daily) or thiazide diuretic (chlorthalidone 12.5-25 mg daily) for hypertension management, as these are not associated with vasculitis and are effective first-line antihypertensive agents 1
The American Diabetes Association suggests restarting or optimizing metformin as first-line therapy for type 2 diabetes if not contraindicated by renal function (eGFR >30 mL/min) 2
The American College of Rheumatology recommends switching to allopurinol once vasculitis has resolved, starting at low dose (≤100 mg daily, lower if CKD present) and titrating to target serum uric acid <6 mg/dL, and testing for HLA-B*5801 allele before starting allopurinol in patients of Southeast Asian descent or African American 3
The American College of Rheumatology suggests providing mandatory gout flare prophylaxis with colchicine (0.5-1 mg daily, dose-adjusted for renal function) or low-dose NSAIDs (if not contraindicated) for at least 6 months when initiating allopurinol 3

The American Heart Association recommends avoiding combining ACE inhibitors with ARBs or renin inhibitors, as this is potentially harmful 1
The American College of Rheumatology suggests never combining allopurinol with febuxostat, as they have redundant mechanisms and increase toxicity without therapeutic benefit 3

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend monitoring renal function, urinalysis, and inflammatory markers (CRP, ESR) weekly initially, then monthly until complete resolution 2